Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status

Psychiatry Research

Volumn 188, Issue 3, 2011, Pages 320-326

  Wing, Victoria C ^a   Bacher, Ingrid ^a   Sacco, Kristi A ^b   George, Tony P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cigarette Smoking; Cognition; Never smoker; Processing Speed; Schizophrenia; Sustained Attention

Indexed keywords

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; REACTIVE INHIBITION; SCHIZOPHRENIA; SELF REPORT; SMOKING HABIT; TASK PERFORMANCE;

ADULT; ANALYSIS OF VARIANCE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING;

EID: 79960700795     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.05.037     Document Type: Article

References (51)

1. Addington J., El-Guebaly N., Campbell W., Hodgins D.C., Addington D. Smoking cessation treatment for patients with schizophrenia. American Journal of Psychiatry 1998, 155:974-976.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 1993, 150:1856-1861.
3. Barr R.S., Culhane M.A., Jubelt L.E., Mufti R.S., Dyer M.A., Weiss A.P., Deckersbach T., Kelly J.F., Freudenreich O., Goff D.C., Evins A.E. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2008, 33:480-490.
4. Berman K.F., Zec R.F., Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention and mental effort. Archives of General Psychiatry 1986, 43:126-135.
5. Connors C.K. The Continuous Performance Test (CPT) 1995, Psychological Assessment Resources, Inc., Odessa, FL.
6. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophrenia Bulletin 1994, 20:31-46.
7. Culhane M.A., Schoenfeld D.A., Barr R.S., Cather C., Deckersbach T., Freudenreich O., Goff D.C., Rigotti N.A., Evins A.E. Predictors of early abstinence in smokers with schizophrenia. Journal of Clinical Psychiatry 2008, 69:1743-1750.
8. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence and schizophrenia: clinical phenomenon and laboratory findings. American Journal of Psychiatry 1998, 155:1490-1501.
9. Depatie L., Driscoll G.A., Holahan A.-L.V., Atkinson V., Thavundayil J.X., Ying Kin N.N., Samarthji L. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002, 27:1056-1070.
10. Dolan S.L., Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C., Wexler B.E., George T.P. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophrenia Research 2004, 70:263-275.
11. Dyer M.A., Freudenreich O., Culhane M.A., Pachas G.N., Deckersbach T., Murphy E., Goff D.C., Evins A.E. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophrenia Research 2008, 102:88-95.
12. Enticott P.G., Ogloff J.R., Bradshaw J.L. Response inhibition and impulsivity in schizophrenia. Psychiatry Research 2008, 157:251-254.
13. Etter M., Mohr S., Garin C., Etter J.F. Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophrenia Bulletin 2004, 30:459-468.
14. Evins A.E., Mays V.K., Rigotti N.A., Tisdale T., Cather C., Goff D.C. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine & Tobacco Research 2001, 3:397-403.
15. Evins A.E., Cather C., Deckerbach T., Freudenreich O., Culhane M.A., Olm-Shipman C.M., Henderson D.C., Schoenfeld D.A., Goff D.C., Rigotti N.A. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. Journal of Clinical Psychopharmacology 2005, 25:218-225.
16. First M.B. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 1994, American Psychiatric Association, Washington, D.C.
17. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry 2008, 165:931-936.
18. George T.P., Zeidonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000, 157:1835-1842.
19. George T.P., Vessicchio J.C., Termine A., Bregartner T.A., Feingold A., Rounsaville B.J., Kosten T.R. A placebo-controlled study of bupropion for smoking cessation in schizophrenia. Biological Psychiatry 2002, 52:53-61.
20. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
21. Goldberg T.F., Weinberger D.R. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophrenia Research 1988, 14:179-183.
22. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. America Journal of Psychiatry 1996, 153:321-330.
23. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction 1991, 86:1119-1127.
24. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtiss G. Wisconsin Card Sorting Test. Manual 1993, Psychological Assessment Resources, Odessa, FL.
25. Hemmingsson T., Kriebel D., Melin B., Allebeck P., Lundberg I. How does IQ affect onset of smoking and cessation of smoking-linking the Swedish 1969 conscription cohort to the Swedish survey of living conditions. Psychosomatic Medicine 2008, 70:805-810.
26. Henik A., Salo R. Schizophrenia and the Stroop effect. Behavioural and Cognitive Neuroscience Reviews 2004, 3:42-59.
27. Hepp H., Maier S., Hermle L., Spitzer M. The Stroop effect in schizophrenic patients. Schizophrenia Research 1996, 22:187-195.
28. Hughes J.R., Hatsukami D.K., Mitchell J.E., Dahlgreen L.A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 1986, 143:993-997.
29. Hughes J.R., Rose G.L., Callas P.W. Do former smokers respond to nicotine differently from never smokers? A pilot study. Nicotine & Tobacco Research 2000, 2:255-262.
30. Jubelt L.E., Barr R.S., Goff D.C., Logvinenko T., Weiss A.P., Evins A.E. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology 2008, 199:89-98.
31. Kalman D., Morrisette S.B., George T.P. Co-morbidity of smoking with psychiatric and substance use disorders. American Journal on Addictions 2005, 14:106-123.
32. Kay S.R., Fiszbein A., Opler L. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
33. Keefe R.S.E., Lees Roitman S.E., Harvey P.D., Blum C.S., DuPre R.L., Prieto R.M., Davidson M., Davis K.L. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research 1995, 17:25-33.
34. Kondel T.K., Mortimer A.M., Leeson V.C., Laws K.R., Hirsch S.R. Intellectual differences between schizophrenic patients and normal controls across the adult lifespan. Journal of Clinical and Experimental Neuropsychology 2003, 25:1045-1056.
35. Lasser K., Boyd J.W., Woolhander S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. Journal of the American Medical Association 2000, 284:2606-2610.
36. Levin E.D., Wilson W., Rose J., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15.
37. Moss T.G., Sacco K.A., Allen T.M., Weinberger A.H., Vessicchio J.C., George T.P. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug and Alcohol Dependence 2009, 104:94-99.
38. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., Freedman R. Proof-of-concept trial of an alpha-7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006, 63:630-638.
39. Park S., Holzman P.S. Schizophrenics show spatial working memory deficits. Archives of General Psychiatry 1992, 49:975-982.
40. Peterson B.S., Skudlarski P., Gatenby J.C., Zhang H., Anderson A.W., Gore J.C. An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems. Biological Psychiatry 1999, 45:1237-1258.
41. Sacco K.A., Termine A., Seyal A.A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking function on spatial working memory and attentional function in schizophrenia: involvement of nicotinic receptor mechanisms. Archives of General Psychiatry 2005, 62:649-659.
42. Sacco K.A., Termine A., Dudas M.M., Seyal A.A., Allen T.M., Vessicchio J.C., Wexler B.E., George T.P. Neuropsychological deficits in non-smokers with schizophrenia: effect of a nicotinic antagonist. Schizophrenia Research 2006, 85:213-221.
43. Sacco K.A., Creeden C.L., Reutenauer E.L., George T.P. Effects of galantamine on neurocognitive deficits in smokers and non-smokers with schizophrenia. Schizophrenia Research 2008, 103:326-327.
44. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002, 27:479-497.
45. Smith R.C., Warner-Cohen J., Matute M., Butler E., Kelly E., Vaidhyanathaswamy S., Khan A. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006, 31:637-643.
46. Stroop J.R. Studies in interference in serial verbal reaction. Journal of Experimental Psychology 1935, 18:643-662.
47. Swick D., Jovanovic J. Anterior cingulate cortex and the Stoop task: neuropsychological evidence for topographic specificity. Neuropsychologia 2002, 40:1240-1253.
48. Weinberger A.H., Reutenauer E.L., Allen T.M., Termine A., Vessicchio J.C., Sacco K.A., Easton C.J., McKee S.A., George T.P. The reliability and internal consistency of the Fagerstrom Test for nicotine dependence, Minnesota Nicotine Withdrawal Scale and Tiffany Questionnaire for smoking urges in cigarette smokers with and without schizophrenia. Drug and Alcohol Dependence 2007, 86:278-282.
49. Weiser M., Zarka S., Werbeloff N., Kravitz E., Lubin G. Cognitive test scores in male adolescent cigarette smokers compared to non-smokers: a population-based study. Addiction 2010, 105:358-363.
50. Woznica A.A., Sacco K.A., George T.P. Prepulse inhibition in patients with schizophrenia and controls: effects of smoking status. Schizophrenia Research 2009, 112:86-90.
51. Ziedonis D.M., Williams J.M. Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry 2003, 16:305-315.